Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.

Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q37128041

about

The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC).Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review.Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study.

P2860

Q28547067-C0705E3E-D2AB-4CA6-BEA5-6D5FBB517505 Q33567383-9AD3660F-6774-4AC8-9F0A-82E87D97B94A Q34130163-EC159DDE-9A44-472D-871E-A67F087A31DD Q36140022-8DEB0904-46BE-4124-B4E6-663776FF9F08 Q36582368-D056670B-1595-424A-89A7-6B7A1DE1DEFD Q37389611-63D5543B-5E7F-4D8D-BA53-C429AE940D99 Q38224482-9C78A2DE-C278-4160-9918-299A6F18D602 Q38390205-2F51BF1F-4F85-4046-A732-9E557775E54F Q42673264-17C0078E-CD45-4E28-B267-9D83AC00B0E8

P2860

Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q37128041

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Re-administration after the fa ...... ed non-small cell lung cancer.

@en

Re-administration after the fa ...... ed non-small cell lung cancer.

@nl

type

label

Re-administration after the fa ...... ed non-small cell lung cancer.

@en

Re-administration after the fa ...... ed non-small cell lung cancer.

@nl

prefLabel

Re-administration after the fa ...... ed non-small cell lung cancer.

@en

Re-administration after the fa ...... ed non-small cell lung cancer.

@nl

P1433

Q37128041-A4B5A1E6-F662-4F95-8526-3836EA0C889F

P1476

Q37128041-240F2AE3-1DB6-4E0C-B707-2BFF6610E5D5

P2093

Q37128041-1F5F7A1A-920D-408D-A40A-665C0F679C86

Q37128041-799E5EAD-E7BA-4A83-9E3F-5269C7FAB313

Q37128041-80DA7E56-831A-41EE-BD8F-FD39CA5FC97A

Q37128041-99DDC2C3-201E-4FDB-902B-470722B57FB6

Q37128041-F3558825-C71A-483F-ADE3-94DEEF92F0BA

P2860

Q37128041-00AFDF1C-BC94-4013-8700-B3834894B8DC

Q37128041-0CE336B6-59C4-4303-BDEF-794F77738F2D

Q37128041-0EC28854-1B08-4B9C-B904-216507AA73F9

Q37128041-0EDD85A0-E4D9-4FA2-9CCC-AE1FB076EE65

Q37128041-0FDCF245-FB25-440F-B531-46FCBA928766

Q37128041-1287F417-2AED-4B88-A2AB-019880B7146D

Q37128041-15E41975-FE3C-41EA-A0AB-EB797BCA33FF

Q37128041-168D6878-4AB8-4209-8A70-89C92B500CAC

Q37128041-2BD80228-8B72-444C-9FF4-10E7B1A98E3A

Q37128041-3861B320-E707-4888-B413-C9A04E993445

P304

Q37128041-E8C4E3DD-A753-41E5-9D8A-25E5D7D34703

P31

Q37128041-3F7A45D8-443E-49DF-B49D-831C93236938

P356

Q37128041-2D6E07E9-8538-410D-9841-27A7C9934620

P433

Q37128041-4E4CD48A-F847-48C4-BD5E-F35D77655FF3

P478

Q37128041-7A3DEB84-CD84-4FB3-B029-1CA0AA2FE3D1

P577

Q37128041-1E50BB5B-B50D-4C18-ADD6-2A94DA7F832B

P698

Q37128041-68F550FA-3E1E-452E-8FB2-F6D6DA425B8F

P932

Q37128041-969A6C86-568F-4806-AE5B-E4D46D8AB177

P356

J.ISSN.2072-1439.2013.07.28

P1433

Journal of thoracic disease

P1476

Re-administration after the fa ...... ed non-small cell lung cancer.

@en

P2093

Beibei Zhang

http://www.w3.org/2001/XMLSchema#string

Chunxiao He

http://www.w3.org/2001/XMLSchema#string

Xinmin Yu

http://www.w3.org/2001/XMLSchema#string

Yiping Zhang

http://www.w3.org/2001/XMLSchema#string

Zhengbo Song

http://www.w3.org/2001/XMLSchema#string

P2860

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Erlotinib in previously treated non-small-cell lung cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

P304

400-405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.2072-1439.2013.07.28

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23991294

http://www.w3.org/2001/XMLSchema#string

P932

3755689

http://www.w3.org/2001/XMLSchema#string